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Adrenocortical tumors (ACTs) are typically unilateral and can be classified as benign 
adrenocortical adenomas (ACAs) or malignant adrenocortical cancers (ACCs). In rare 
cases, tumors may occur in both adrenal glands as micronodular hyperplasia (primary 
pigmented nodular adrenal dysplasia) or as macronodular hyperplasia (primary bilateral 
macronodular adrenal hyperplasia, PBMAH). The study of certain tumor predisposition 
syndromes has improved our understanding of sporadic ACTs. Most ACAs are associated 
with abnormalities of the cAMP signaling pathway, whereas most ACCs are linked to 
alterations in IGF2, TP53, or the Wnt/βcatenin pathways. Over the past year, single- 
nucleotide polymorphism array technology and next-generation sequencing have identified 
novel genetic alterations in ACTs that shed new light on the molecular mechanisms of 
oncogenesis. Among these are somatic mutations of PKA catalytic subunit alpha gene 
(PRKACA) in ACA, germline, and somatic mutations of armadillo repeat containing 5 gene 
(ARMC5) in primary bilateral macronodular adrenal hyperplasia and somatic alterations of 
the E3 ubiquitin ligase gene ZNRF3 in ACC. This review focuses on the recent discoveries 
and their diagnostic, prognostic, and therapeutic implications.
Keywords: adrenocortical adenoma, hyperplasia, adrenocortical carcinoma, PRKACA, ARMC5, ZnRF3
introduction
The pathogenic mechanisms underlying adrenocortical tumors (ACTs) are complex and hetero-
geneous. The most common ACT is benign, unilateral, non-secreting (adrenocortical adenomas, 
ACAs-NS), and often discovered incidentally. ACTs exist in the bilateral form but are much less 
frequent. The symptoms due to ACT are caused by steroid excess (Cushing’s syndrome) in the case 
of secreting benign tumors. The aggressive and deadly forms of ACT are adrenocortical cancers 
(ACCs) but have an overall low incidence of appearance. The clinical consequences of ACC can be 
due to steroid oversecretion, tumor growth, or metastasis. ACCs are rare and show heterogeneity in 
malignancy, in levels of hormone secretion, and in tumor progression. It is also difficult to predict 
evolution and prognosis although these cancers are globally associated to poor outcome.
Till now, the majority of genetic and molecular alterations of benign tumors has been closely 
linked to abnormalities in the cAMP signaling pathway. Somatic and germline mutations were 
identified in actors of the cAMP pathway as the PRKAR1A gene (regulatory subunit of the cAMP-
dependent protein kinase A) (1, 2), GNAS gene (α subunit of the stimulatory G protein) (3), and 
the PDE11A/8B genes (cAMP-degrading phosphodiesterase 11A and 8B, respectively) (4, 5). Other 
alterations modulating the cAMP/PKA pathway activity that stimulates steroidogenesis are present 
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in ACA. For example, ectopic expression of the gastric inhibitory 
polypeptide receptor (GIPR) in the human adrenal gland causes 
significant hypercortisolemia after meal ingestion and leads to 
Cushing’s syndrome (6, 7). Ectopic expression of other receptors 
belonging to binding G protein-coupled receptors classes such as 
vasopressin, serotonin, and catecholamine receptors have been 
described in the bilateral hyperplasias of the adrenal cortex and 
cortisol-secreting adenomas (ACA-S) (8, 9). In contrast to ACA, 
ACCs have been related to alterations in various pathways such 
as IGF2, TP53, or Wnt/βcatenin. Initially, progress in identifying 
genes involved in sporadic ACT came mainly from the study of rare 
familial cases (10–12): TP53 tumor suppressor gene and its predis-
position’s locus on chromosome 17p13.1 involved in Li–Fraumeni 
syndrome; the imprinted gene encoding the insulin-like growth 
factor IGF2, located on chromosome 11p15.5 and associated with 
Beckwith–Wiedemann syndrome, germline PRKAR1A mutations 
identified in Carney complex. Moreover, somatic mutations in the 
CTNNB1 gene have been reported in both benign and malignant 
ACTs (13). However, alterations in these several genes are identi-
fied only in subgroups of ACA and ACC. Over the last 5 years, the 
development of high-throughput sequencing has revealed several 
frequent alterations in genes not previously described, underlying 
new insights in the pathogenesis of benign and malignant forms of 
ACT. For example, a hotspot somatic mutation in the PKA catalytic 
subunit alpha gene (PRKACA) has been identified in ACA (14), 
germline, and somatic mutations of armadillo repeat containing 
5 gene (ARMC5) have been described in patients with primary 
bilateral macronodular adrenal hyperplasia (PBMAH) (15), and 
somatic alterations in the E3 ubiquitin ligase gene ZNRF3 were 
recently identified in ACC (16). In this review, we aim to give 
an overview of recent advances in the genetics of ACT, focusing 
on the latest driver genes identified, and therefore improving our 
understanding of the pathophysiology of these tumors.
Adrenocortical Adenomas
Prior to the introduction of next-generation sequencing, mutations 
in some genes such as GNAS or PRKAR1A had been reported 
in ACA-S. Activating mutations of the GNAS alpha subunit 
(17) and PRKAR1A-inactivating mutations (18) promote the 
cAMP pathway activation. CTNNB1-activating mutations had 
been found in ACA-NS and ACA-S but their prevalence was 
higher among ACA-NS (13, 19, 20). However, these mutations 
accounted for only a subset of ACA. Recently, Beuschlein and col-
laborators identified a hotspot mutation in PRKACA gene through 
whole-exome sequencing in ACA-S (14). The somatic mutation, 
p.L206R/c.617A > G was present in more than one-third of the 
examined tumors. This result was confirmed by four other groups, 
which has reported the same recurrent mutation in the PRKACA 
gene (21–24). This mutation occurs in the C-terminus of the activa-
tion segment in the p + 1 loop of PRKACA protein (Figure 1A). 
This region is a specific binding site for the interaction between 
catalytic and regulatory subunits of PKA (25). The p.L206R point 
mutation results in the introduction of a voluminous and positively 
charged amino acid that inhibits the formation of stable complexes 
between subunits of PKA (23, 24, 26). This mutation prevents the 
interaction of the catalytic subunit of PKA with the regulatory 
subunit, resulting in an increased phosphorylation of substrates 
and finally, in an excessive steroidogenic activity (Figure 2A). The 
consequence of this lack of interaction has been shown for both 
RIA (PRKAR1A) and RIIB (PRKAR2B) regulatory subunits (26). 
L206R mutation of PRKACA in ACA-S was associated with more 
severe phenotypes (Cushing’s syndrome) (14). Another mutation 
in the PRKACA gene, Leu199_Cys200insTrp, identified only in one 
study, has the same effect on the stability of the PKA complex (14, 
26) (Figures 1A and 2A).
Adrenal cortex and cortisol-secreting adenomas are charac-
terized by a high occurrence of PRKACA-activating mutations. 
However, other mutations in GNAS and CTNNB1 genes are found 
in some ACA-S without PRKACA mutations and are mutually 
exclusive (21, 23). The hotspot mutation in the PRKACA gene 
seems to be sufficient to alter the endocrine and proliferative 
systems in ACA-S and represents the main genetic risk factor 
associated with this type of tumor (14, 21–24).
Primary Bilateral Macronodular Adrenal 
Hyperplasia
Primary bilateral macronodular adrenal hyperplasia described first 
in 1964 is a rare type of bilateral ACTs leading to adrenal Cushing’s 
syndrome (33). PBMAH are often revealed incidentally during 
radiological examinations or by the presence of overt Cushing’s 
syndrome. Both adrenal glands are enlarged massively with the 
presence of numerous macronodules. This adrenal disorder is 
usually diagnosed in patients aged between 40 and 60. In addi-
tion to ectopic expression of G protein-coupled receptors, it has 
been described in PBMAH an abnormal expression of paracrine 
factors (34–36). For instance, recently, an ACTH production by 
adrenocortical cells was reported in a large series of PBMAH, 
which can play a role in cortisol hypersecretion (36). Despite the 
fact that most cases of PBMAH appeared to be sporadic, some 
familial cases were reported, supporting the idea of a germline 
hereditary factor. Mutations or variants of some genes involved 
in the cAMP signaling pathway have been identified as in GNAS, 
PDE11A, and PDE8B genes but are only present in a limited frac-
tion of PBMAH cases.
Combining single-nucleotide polymorphism (SNP) array 
and whole-genome sequencing, the first gene predisposing to 
PBMAH in adults has been recently identified (15). The most 
frequent somatic chromosome alteration in PBMAH was a loss 
of heterozygosity (LOH) at 16p and, the most frequent mutation 
identified was in ARMC5 gene, located at 16p11.2. ARMC5 altera-
tions were detected in tumors obtained from 18 of 33 patients 
who had undergone surgery (55%). In all cases, both alleles of 
ARMC5 carried alteration: one germline and the other somatic. 
For some cases with an ARMC5 germline mutation, different 
nodules from one or both adrenal glands were analyzed. In each 
case, the same germline mutation was detected in all nodules 
and associated with a nodule-specific second somatic ARMC5 
alteration (LOH, nonsense or missense mutation). The discovery 
of ARMC5 alterations establishes the first direct genetic link to 
PBMAH. The pattern of mutations suggests a “two-hit” model of a 
tumor suppressor gene, responsible for a hereditary predisposition 
syndrome. Subsequent studies confirm the recurrent mutation of 
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ARMC5 in family members with PBMAH (27–30). In these various 
studies, the percentage of ARMC5 mutations reaches 25% in index 
cases of PBMAH. Recently, the high frequency of alterations in the 
ARMC5 gene has been confirmed in a large cohort of 98 patients 
FiguRe 1 | Location of mutations in PRKACA, ARMC5, and ZnRF3. 
Full length of PRKACA (A), ARMC5 (B), and ZNRF3 (C) proteins were 
represented with mutations identified in ACA-S (14, 21–24), PBMAH (15, 
27–32), and ACC (16), respectively. Somatic mutations are shown in purple, 
while germline mutations in black. Gray star and filled gray circles represent 
mutations identified in a meningioma (31) and in patients with 
hyperaldosteronism (32), respectively. ND, germline or somatic status not 
determined.
with PBMAH, including operated and non-operated patients 
(31). Up to now, these recent studies identified – in patients with 
PBMAH – in addition to LOH and a microdeletion, a total of 61 
different mutations in ARMC5: 27 germinal, 30 somatic, two which 
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have been identified at somatic and germline levels in different 
cases (p.R315W and p.R619X) and two without status available 
(Figure 1B). All these mutations can be found all along the protein 
in different domains. Two of the germline mutations are found in 
several index cases and in at least three studies suggesting a founder 
effect: p.R267X and p.R898W (15, 27–32).
The ARMC5 encodes a protein of 935 amino acids and the 
peptide sequence reveals two distinctive domains: ARM domain 
in the N-terminal and a BTB/POZ in the C-terminal (Bric-a-Brac, 
Tramtrack, Broad-complex/Pox virus, and Zinc finger) (Figure 1B). 
These domains are highly conserved through evolution and have been 
shown to be involved in mediating protein-protein interactions, but 
targeted proteins recognition by these domains is not understood 
yet. The mechanism of ARMC5 action is unknown because no study 
has ever been focused on its biological function, and no diseases have 
been associated with the ARMC5 gene until now. Recent functional 
study on ARMC5 gene, performed in the human adrenocortical cells 
H295R, showed that ARMC5 gene silencing alters the expression of 
genes involved in steroidogenesis leading to a global decreased of 
cortisol secretion (15) (Figure 2B). These data are consistent with 
previous expression-profile studies (37, 38). It is therefore likely 
that, despite the reduced secretory capacity of each cell, the overall 
production of cortisol was increased because of the large adrenal 
mass. All data describing ARMC5 mutations show that patients 
suffering from PBMAH have a phenotype more severe than patients 
without ARMC5 mutation (15, 31). Patients with ARMC5 mutations 
present with larger tumor volumes, increased numbers of tumor 
nodules, and more severe hypercortisolism (31). Recently, ARMC5 
mutations have been associated with another steroid hypersecretion. 
Indeed, six patients of 56 (10.7%) with primary hyperaldosteron-
ism had germline mutations in the ARMC5 gene. Among these six 
patients, two suffered from PBMAH (32).
The genomic and functional data indicate that ARMC5 has a 
role of tumor suppressor gene because two inactivating mutations 
seem necessary to develop PBMAH and human cells (H295R and 
HeLa) transfected with non-mutated ARMC5 resulted in cell death 
(Figure 2B). In contrast, this effect was not observed with missense 
mutations. This suggests that ARMC5 plays a significant role in 
cell apoptosis (15, 31).
Bilateral adrenalectomy is considered as the single treatment 
of choice for PBMAH, the finding of ARMC5 gene is promising 
for the discovery of new therapeutic perspectives. Interestingly, 
a somatic mutation in ARMC5 gene has also been found in a 
meningioma in patients with an ARMC5 germline mutation and 
a PBMAH (30). These data suggest that genetic alterations of the 
ARMC5 gene may cause the development of different associated 
tumors with PBMAH. With the recent advances in the genetic 
methods, it is possible to imagine that future studies will reveal 
cases with ARMC5 mutations in other types of tumors without 
PBMAH. Now, it is necessary to better know the functional role 
of the ARMC5 protein in order to understand the impact of these 
mutations on the initiation and/or development of PBMAH.
Mutations in the DOT1L (DOT1-like histone H3K79 methyl-
transferase) and HDAC9 (histone deacetylase 9) genes have also 
been found in patients with PBMAH. Unlike ARMC5 mutations, 
their frequency is lower and appeared only in two and one cases, 
respectively. These new mutations seem to define a little subgroup 
FiguRe 2 | effects of recently identified drivers in signaling pathways 
involved in adrenal tumorigenesis. (A) Alterations in the PKA pathway 
caused by PRKACAp.L206R and PRKACALeu199_Cys200insTrp mutations in 
adrenocortical adenomas. Under normal conditions, the catalytic and 
regulatory subunits of PKA form a heterotetramer. In response to ACTH 
stimulation, the catalytic subunits are released from the complex in an active 
form. The free catalytic subunits phosphorylate their substrates and thereby 
increase the transcription of target genes. These target genes are mainly 
involved in the synthesis of cortisol and other steroids. The p.L206R and 
Leu199_Cys200insTrp mutations in the PRKACA gene alter its interaction with 
regulatory subunits of PKA leading to constitutive activation of PKAcα and 
increased steroidogenesis. (B) ARMC5, a new indirect or direct regulator of 
steroidogenic and apoptosis processes. ARMC5 inactivating mutations induce 
a decreased steroidogenic capacity and a protection against cell death.  
(C) ZNRF3 a negative feedback regulator of the Wnt/β-catenin signaling 
pathway. 1, In the absence of R-spondin (RPSO), ZNRF3 induces the 
poly-ubiquitination of Frizzled receptors (FZD) that promote their degradation. 
2, In the presence of RSPO, ZNRF3 interacts with the complex RSPO/LGR4, 
which results in the turnover of ZNRF3 and thus the stability of FZD and the 
stimulation of Wnt/β-catenin signaling. 3, In ACC, ZNRF3 alterations can 
produce similar effects of RSPO stimulation leading to an activation of 
Wnt/β-catenin signaling. Red stars represent mutated or altered proteins.
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have been identified at somatic and germline levels in different 
cases (p.R315W and p.R619X) and two without status available 
(Figure 1B). All these mutations can be found all along the protein 
in different domains. Two of the germline mutations are found in 
several index cases and in at least three studies suggesting a founder 
effect: p.R267X and p.R898W (15, 27–32).
The ARMC5 encodes a protein of 935 amino acids and the 
peptide sequence reveals two distinctive domains: ARM domain 
in the N-terminal and a BTB/POZ in the C-terminal (Bric-a-Brac, 
Tramtrack, Broad-complex/Pox virus, and Zinc finger) (Figure 1B). 
These domains are highly conserved through evolution and have been 
shown to be involved in mediating protein-protein interactions, but 
targeted proteins recognition by these domains is not understood 
yet. The mechanism of ARMC5 action is unknown because no study 
has ever been focused on its biological function, and no diseases have 
been associated with the ARMC5 gene until now. Recent functional 
study on ARMC5 gene, performed in the human adrenocortical cells 
H295R, showed that ARMC5 gene silencing alters the expression of 
genes involved in steroidogenesis leading to a global decreased of 
cortisol secretion (15) (Figure 2B). These data are consistent with 
previous expression-profile studies (37, 38). It is therefore likely 
that, despite the reduced secretory capacity of each cell, the overall 
production of cortisol was increased because of the large adrenal 
mass. All data describing ARMC5 mutations show that patients 
suffering from PBMAH have a phenotype more severe than patients 
without ARMC5 mutation (15, 31). Patients with ARMC5 mutations 
present with larger tumor volumes, increased numbers of tumor 
nodules, and more severe hypercortisolism (31). Recently, ARMC5 
mutations have been associated with another steroid hypersecretion. 
Indeed, six patients of 56 (10.7%) with primary hyperaldosteron-
ism had germline mutations in the ARMC5 gene. Among these six 
patients, two suffered from PBMAH (32).
The genomic and functional data indicate that ARMC5 has a 
role of tumor suppressor gene because two inactivating mutations 
seem necessary to develop PBMAH and human cells (H295R and 
HeLa) transfected with non-mutated ARMC5 resulted in cell death 
(Figure 2B). In contrast, this effect was not observed with missense 
mutations. This suggests that ARMC5 plays a significant role in 
cell apoptosis (15, 31).
Bilateral adrenalectomy is considered as the single treatment 
of choice for PBMAH, the finding of ARMC5 gene is promising 
for the discovery of new therapeutic perspectives. Interestingly, 
a somatic mutation in ARMC5 gene has also been found in a 
meningioma in patients with an ARMC5 germline mutation and 
a PBMAH (30). These data suggest that genetic alterations of the 
ARMC5 gene may cause the development of different associated 
tumors with PBMAH. With the recent advances in the genetic 
methods, it is possible to imagine that future studies will reveal 
cases with ARMC5 mutations in other types of tumors without 
PBMAH. Now, it is necessary to better know the functional role 
of the ARMC5 protein in order to understand the impact of these 
mutations on the initiation and/or development of PBMAH.
Mutations in the DOT1L (DOT1-like histone H3K79 methyl-
transferase) and HDAC9 (histone deacetylase 9) genes have also 
been found in patients with PBMAH. Unlike ARMC5 mutations, 
their frequency is lower and appeared only in two and one cases, 
respectively. These new mutations seem to define a little subgroup 
FiguRe 2 | effects of recently identified drivers in signaling pathways 
involved in adrenal tumorigenesis. (A) Alterations in the PKA pathway 
caused by PRKACAp.L206R and PRKACALeu199_Cys200insTrp mutations in 
adrenocortical adenomas. Under normal conditions, the catalytic and 
regulatory subunits of PKA form a heterotetramer. In response to ACTH 
stimulation, the catalytic subunits are released from the complex in an active 
form. The free catalytic subunits phosphorylate their substrates and thereby 
increase the transcription of target genes. These target genes are mainly 
involved in the synthesis of cortisol and other steroids. The p.L206R and 
Leu199_Cys200insTrp mutations in the PRKACA gene alter its interaction with 
regulatory subunits of PKA leading to constitutive activation of PKAcα and 
increased steroidogenesis. (B) ARMC5, a new indirect or direct regulator of 
steroidogenic and apoptosis processes. ARMC5 inactivating mutations induce 
a decreased steroidogenic capacity and a protection against cell death.  
(C) ZNRF3 a negative feedback regulator of the Wnt/β-catenin signaling 
pathway. 1, In the absence of R-spondin (RPSO), ZNRF3 induces the 
poly-ubiquitination of Frizzled receptors (FZD) that promote their degradation. 
2, In the presence of RSPO, ZNRF3 interacts with the complex RSPO/LGR4, 
which results in the turnover of ZNRF3 and thus the stability of FZD and the 
stimulation of Wnt/β-catenin signaling. 3, In ACC, ZNRF3 alterations can 
produce similar effects of RSPO stimulation leading to an activation of 
Wnt/β-catenin signaling. Red stars represent mutated or altered proteins.
of PBMAH without ARMC5 mutations (21). DOT1L and HDAC9 
are methyltransferase and histone deacetylase, respectively; these 
two nuclear proteins are involved in the transcriptional regulation. 
Further investigations will help to delineate the importance of these 
three genes in the adrenal function. In regard to the high frequency 
(20%) of mutations in ARMC5 gene in all index cases analyzed, its 
systematic genetic screening appears to be important for patients with 
PBMAH or Cushing syndrome. This screening can be used for early 
detection of PBMAH in family members with no clinical evidence.
Adrenocortical Cancer
ACC is a rare and highly aggressive endocrine tumor that affects 
one to two persons per 1 million of the population per year (39). 
The prognosis of ACC is very poor, with a 5-year survival rate 
under 35% in most series (40–43). Currently, surgery is the only 
curative therapy available. Medical treatments, including the 
adrenolytic drug mitotane and cytotoxic chemotherapy, show 
only limited therapeutic potential (44). The rarity of ACC is a 
limiting factor in the progress to understand the pathophysiology 
of this tumor. Up to now, somatic inactivating mutations of the 
tumor suppressor gene TP53 and activating mutations of the proto-
oncogene β-catenin (CTNNB1) were the most frequent mutations 
identified in ACC (13, 42, 45, 46).
Recently, a cohort of 122 ACC, from the European Network 
for the Study of Adrenal Tumors (ENSAT), was analyzed by SNP 
array. Fifty-five of these 122 ACC have also been analyzed by a 
combination of other genomic approaches, including exome 
sequencing, DNA methylation, mRNA expression arrays, and 
miRNA sequencing. Candidate driver genes were validated by 
targeted sequencing in all tumors. This work confirmed recurrent 
alterations in the known drivers CTNNB1 and TP53 and revealed 
new genes not previously reported to be altered in ACC. Strikingly, 
ZNRF3 (Zinc and ring finger protein 3) was the most frequently 
altered gene (21%). In a majority of cases, homozygous deletions 
of ZNRF3 were observed but few somatic inactivating mutations 
and two missense mutations were also identified (16) (Figure 1C).
ZNRF3 and its homolog RNF43 (ring finger protein 43) encode 
proteins with E3 ubiquitin ligase activity that have recently been 
described as cell-surface transmembrane E3 ubiquitin ligases, 
acting as negative feedback regulators of Wnt/β-catenin signal-
ing. ZNRF3 and RNF43 contain a signal peptide, an extracellular 
domain for R-spondin (RSPO)-binding, a single transmenbrane 
helix, a cytoplasmic really interesting new gene (RING) finger 
domain, and a C-terminal tail. It has been demonstrated that 
ZNRF3/RNF43 are associated with the Wnt receptors (Frizzled, 
FZD), which results in a multi-ubiquitination of lysines in the 
intracellular domain of FZD and then their internalization and 
degradation in lysosomes (47, 48). RSPO are secreted proteins 
known to potentiate the Wnt signaling. Various membrane pro-
teins have been reported to bind RSPO, including FZD and LRP6, 
LGR4/5/6, Kremen, Syndecan, and ZNRF3/RNF43 (49). Several 
models of RSPO signaling have been proposed. Recently, published 
data indicate that the ZNRF3/RNF43-mediated membrane clear-
ance of FZD is reversed upon addition of RSPO (47, 49, 50). Once 
bound to its receptor (LGR5), RSPO are believed to decoy ZNRF3, 
thus permitting strong β-catenin signaling (Figure 2C).
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It has been shown that ZNRF3 protein expression is down 
regulated in gastric adenocarcinoma tissues compared with 
adjacent normal gastric tissues (51). Recurrent deletion of three 
regions in chromosome 22 was identified in osteoblastoma, one 
of these regions contains ZNRF3 (52). Moreover, the deletion of 
ZNRF3 and RNF43 in the intestinal epithelium in mouse induces 
the development of adenoma with an increased nuclear β-catenin 
and an increased expression of Wnt/β-catenin target genes (48).
Interestingly alterations of ZNRF3 and CTNNB1 are completely 
exclusive in ACC (16), suggesting that ZNRF3 alterations might 
play a crucial role in tumorigenesis by activating also the Wnt/β-
catenin signaling pathway. Taken together, 37% of ACC samples 
harbored an alteration affecting the Wnt pathway. These data 
strongly suggest that in ACC, ZNRF3 is a tumor suppressor gene 
related to the Wnt pathway. ACC with altered ZNRF3 showed tran-
scriptional activation of β-catenin targets, but this activation was 
weaker than in CTNNB1-mutated tumors (16). However, till now, 
ACCs are the cancers described with the most frequent ZNRF3 
alterations, suggesting a specific mechanism of tumorigenesis into 
the adrenal cortex tissue. Future functional studies are needed to 
investigate its role in adrenocortical cells.
Conclusion
Analyses of inherited syndromes associated with an increased risk 
adrenocortical tumorigenesis, coupled with recent advances in 
sequencing technology, have improved our understanding of 
ACT. Recent advances in genomic tools, especially sequencing 
technologies, have yielded new findings in three types of ACT. 
Alterations in genes not previously reported were identified: 
somatic mutations of PRKACA gene in ACA, germline and 
somatic mutations of ARMC5 gene in PBMAH, and somatic 
alterations of ZNRF3 gene in ACC.
It would be worth pursuing functional studies on these genes 
in order to understand the impact of these alterations on the 
initiation and/or development of ACT. The identification of sign-
aling pathways playing a major role in ACT development would 
help to develop new targeted therapies, which are dramatically 
needed for the management of patients harboring these tumors, 
especially for ACC.
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